TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity

ROS1 rearrangement is observed in 1–2% of non-small cell lung cancers (NSCLC). The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has induced marked tumour shrinkage in ROS1-rearranged cancers. However, emergence of acquired resistance to TKI is inevitable within a few years. Previous findings indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Hayato, Nagatake-Kobayashi, Yuka, Adachi, Jun, Tomonaga, Takeshi, Fujita, Naoya, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514057/
https://www.ncbi.nlm.nih.gov/pubmed/28717217
http://dx.doi.org/10.1038/s41598-017-05736-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514057/
https://www.ncbi.nlm.nih.gov/pubmed/28717217
http://dx.doi.org/10.1038/s41598-017-05736-9

Ejemplares similares